MYOM2 and Miyoshi myopathy: The iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) study, which involved Icelanders over the age of 40, discovered a high prevalence of smoldering MM (SMM) by screening the general population for M‐protein.10, 11